Econ One economists and statisticians have extensive experience with pharmaceutical and health care markets. Combining economic expertise with in-depth industry knowledge, Econ One has provided economic and statistical analysis on a broad range of antitrust, contract dispute, false claims, and reimbursement matters. Our comprehensive understanding of publicly available and confidential data sets such as health insurance claims from Medicare, Medicaid, and commercial payors; usual and customary benchmarks for provider bill charges; and transactional data maintained by pharmaceutical manufacturers regarding sales and net pricing differentiates us in our ability to use large quantities of data on issues such as damages, relevant market, industry characteristics, and other relevant topics.
Econ One has worked extensively with counsel for direct purchasers of various pharmaceuticals on generic delay cases such as pay-for-delay and product hopping, and in antitrust disputes over alleged monopolization in contract pricing and reimbursement for the provision of health care services. In these cases we have used econometric and economic analysis to asses whether common evidence can be used to determine impact and damages on a class-wide basis. Our analyses in these cases often have focused on defining relevant markets, assessing market power, determining the competitive effects of the allegedly anticompetitive behavior, and calculating overcharges.
Econ One experts bring a rich foundation in statistics to our work, such as sampling in False Claims Act cases, bench marking usual and customary rates for out-of-network provider billed charges, and empirical analysis of prescription drug reimbursement based on average wholesale prices.